Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, MutantIDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

Courtney D. DiNardo,Stephane de Botton,Alberto Risueno,Andre C. Schuh,Bob Loewenberg,Hee-Je Kim,Paresh Vyas,Andrew H. Wei,Eytan M. Stein,Hartmut Dohner,Amir T. Fathi,Patricia Martin-Regueira,Lilia Taningco,Iryna Bluemmert,Xin Yu,Wendy L. See,Maroof Hasan

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览24

暂无评分

摘要

Mutational burden and co-mutational profiles differed between patients with mIDH2-R140 and mIDH2-R172 relapsed/refractory AML. In the R172 subgroup, median OS and 1-year survival rate with enasidenib were approximately double those with CCR.

查看译文

关键词

AML, enasidenib, IDH2, relapsed/refractory, biomarkers, Phase III

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要